Pfizer-BioNTech Says Covid-19 Vaccine Is 95% Effective, Will Seek Emergency Approval Within Days
Pfizer and BioNTech are preparing to submit their Covid-19 vaccine for emergency use approval in the U.S. and the EU after new trial data showed it to be 95% effective, following initial news of 90% efficacy in its Phase 3 trials.
New findings from Phase 3 clinical trials, which enrolled over 43,000 people to test the two-dose Covid-19 vaccine, show the vaccine to be effective at preventing Covid-19 in 95% of cases, an improvement on earlier results indicating the vaccine to be 90% effective.
The companies say the findings are consistent across various demographics, including age, race and ethnicity, with the vaccine still more than 94% effective in adults over the age of 65.
This is a developing story, check back for updates.